Endothelin Receptor Antagonists

Angiotensin 2 Receptor Blocker

Endothelin Receptor Antagonist

Angiotensin 2 Type 1 Receptor Antagonists

P-Glycoprotein Inhibitors

Cytochrome P450 2C9 Inducers

Cytochrome P450 2C19 Inducers

Cytochrome P450 2B6 Inducers

Breast Cancer Resistance Protein Inhibitors

Proteinuria

<section class="Section" data-sectioncode="34089-3"><a name="Section_11"></a><a name="section-10"></a><h1>11  DESCRIPTION</h1><a name="P25"></a>FILSPARI (sparsentan) is an endothelin and angiotensin II receptor antagonist. The chemical name of sparsentan is 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-N-(4,5-dimethyl-1,2-oxazol-3-yl)benzenesulfonamide.<a name="p8034301644374946"></a>Sparsentan is a white to off-white powder, which is practically insoluble in water. Sparsentan has pH-dependent solubility, with intrinsic solubility of 1.48 and 0.055 mg/mL under pH 1.2 and 6.8, respectively. Sparsentan has a molecular weight of 592.76 g/mol, a molecular formula of C32H40N4O5S, and the following structure:<img alt="Sparsentan Structure" src="Sparsentan_Structure.jpg"/><a name="p8064301644374954"></a>FILSPARI is available as film-coated 200 mg and 400 mg strength immediate release tablets for oral administration.<a name="p615546861662604932"></a>The inactive ingredients in FILSPARI are colloidal silicon dioxide, lactose anhydrous, magnesium stearate, silicified microcrystalline cellulose, and sodium starch glycolate. Film-coating is composed of macrogol/polyethylene glycol, polyvinyl alcohol-partially hydrolyzed, talc, and titanium dioxide.</section>

FILSPARI

sparsentan

sparsentan 200 MG Oral Tablet

Filspari

sparsentan 200 MG Oral Tablet [Filspari]

sparsentan 400 MG Oral Tablet

sparsentan 400 MG Oral Tablet [Filspari]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information

Medication Guide 

Submit MSL Request 

Pharmacy List

Reimbursement Information

Coverage Authorization Request 

Coverage Authorization Appeals 

Letter of Medical Necessity

PA Checklist 

Appeals Checklist

Filspari Start Form & Prescription

Filspari Start & Prescription Form - Online 

Filspari REMS Prescriber Form 

Enroll in Patient Savings Program 

About Filspari 

Filspari Start Guide 

Filspari Travere Total Care Program 

FAQs: Primary Immunoglobulin A Nephropathy (IgAN) 

Patient Resources 

Instructions For Use:  Primary Immunoglobulin A Nephropathy (IgAN) 

Patient Brochure 

Doctor Discussion Guide 

Patient Consent Form - Spanish

Patient Consent Form - Mandarin